<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02618187</url>
  </required_header>
  <id_info>
    <org_study_id>SERES-101</org_study_id>
    <nct_id>NCT02618187</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Ulcerative Colitis</brief_title>
  <official_title>A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seres Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seres Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287
      in Subjects with Mild-to-Moderate Ulcerative Colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b multicenter, randomized, double-blind, placebo-controlled multiple dose
      study designed to evaluate the safety and tolerability of SER-287, and to evaluate the
      microbiome alterations and pharmacodynamics associated with 2 dosing regimens of SER-287 in
      adult subjects with mild-to-moderate ulcerative colitis (UC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of SER-287 vs. placebo in adult subjects by analysis of AE's, lab values, vital sign, physical exam findings, medical history, and ECG.</measure>
    <time_frame>Day 246</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Examination of baseline composition of the intestinal microbiome to the composition</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changes in the composition of the microbiome will be characterized by rDNA 16S V4 genomic data sets. Changes will be assessed by total number of unique bacteria and microbial composition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Engraftment of SER-287 bacteria into the intestinal microbial community in each of the SER-287 arms compared to the placebo arm</measure>
    <time_frame>8 weeks</time_frame>
    <description>Microbiome will be characterized by rDNA 16S v4 Genomic Data Sets. Engraftment will be assessed as the outgrowth of bacteria that compromise the SER-287 spore ecology in the subjects GI tract post treatment</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Placebo Pre-Treat + Weekly Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Pre-Treat + Daily placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pre-treatment, followed by once daily placebo for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic Pre-Treat + Daily Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin pre-treatment, followed by once daily dosing of SER-287 for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anitibiotic Pre-Treat + Weekly Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin pre-treatment, followed by once weekly dosing of SER-287 for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eubacterial Spores, Purified Suspension, Encapsulated</intervention_name>
    <arm_group_label>Placebo Pre-Treat + Weekly Drug</arm_group_label>
    <arm_group_label>Antibiotic Pre-Treat + Daily Drug</arm_group_label>
    <arm_group_label>Anitibiotic Pre-Treat + Weekly Drug</arm_group_label>
    <other_name>SER-287</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Pre-Treat + Daily placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Pre-Treat</intervention_name>
    <arm_group_label>Placebo Pre-Treat + Weekly Drug</arm_group_label>
    <arm_group_label>Placebo Pre-Treat + Daily placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Pre-Treat</intervention_name>
    <arm_group_label>Antibiotic Pre-Treat + Daily Drug</arm_group_label>
    <arm_group_label>Anitibiotic Pre-Treat + Weekly Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ulcerative colitis diagnosed by routine clinical, radiographic, endoscopic and
             pathologic criteria (preferably confirmed by colonoscopy and pathology records within
             last 2 years or if unavailable, will need approval by medical monitor) Active
             mild-moderate UC as determined by sigmoidoscopy within approximately 3 days of
             randomization to study

        Exclusion Criteria:

          1. Fever &gt; 38.3Â°C

          2. Known or suspected toxic megacolon and/or known small bowel ileus

          3. Known history of Crohn's disease

          4. Subjects with serum albumin &lt;2.5 g/dL at baseline

          5. CMV polymerase chain reaction (PCR) positive from blood plasma at screening

          6. Known stool studies positive for ova and/or parasites or stool culture within the 30
             days before enrollment

          7. Subjects on cyclosporine or triple immunosuppression, Triple immunosuppression will
             include any three of the following classes of drugs taken in combination: steroids
             (i.e., prednisone/budesonide/budesonide MMX), immunosuppressant (i.e.,
             methotrexate/azathioprine/6-mercaptopurine), and/or other immunosuppressant (i.e.,
             tacrolimus, cellcept).

          8. Biologic medication (infliximab/ adalimumab/ golimumab/
             certolizumab/vedolizumab/ustekinumab/natalizumab) use within 3 months prior to
             screening

          9. Known active malignancy except for basal cell skin cancer, squamous cell skin cancer

         10. Subjects with previous colectomy, ostomy, J-pouch, or previous intestinal surgery
             (excluding cholecystectomy, appendectomy)

         11. Subjects with known history of celiac disease or gluten enteropathy

         12. Subjects with Clostridium difficile positive stool at Screening Visit

         13. Antibiotic use within the prior 1 month before randomization

         14. Expected to receive antibiotics within 8 weeks of signing the Informed Consent Form
             (ICF) (i.e., for planned/anticipated procedure)

         15. Received an investigational drug within 1 month before study entry

         16. Received an investigational antibody or vaccine within 3 months before study entry

         17. Previously enrolled in a SER-109/SER-287 study

         18. Received an FMT within the last 6 months

         19. Subjects with anatomic or medical contraindications to flexible sigmoidoscopy,
             including but not necessarily limited to toxic megacolon, gastrointestinal (GI)
             fistulas, immediate post-operative status from abdominal surgery, severe coagulopathy,
             large or symptomatic abdominal aortic aneurysm, or any subject where study physician
             deems subject at significant risk of complications of flexible sigmoidoscopy

         20. Unable to stop steroid enemas or suppositories or mesalamine enemas or suppositories
             before screening visit

         21. Unable to stop opiate treatment unless on a stable dose and no increase in dose
             planned for the duration of the study

         22. Unable to stop probiotics before screening visit

         23. Concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for
             active malignancy (subjects on maintenance chemotherapy may only be enrolled after
             consultation with medical monitor)

         24. Known allergy or intolerance to oral vancomycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michele Trucksis, PhD, MD</last_name>
    <email>clinicalstudies@serestherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene Romo</last_name>
      <phone>909-586-6243</phone>
      <email>dromo@ieliverfoundation.com</email>
    </contact>
    <investigator>
      <last_name>Zeid Kayali</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryLu Wells</last_name>
      <phone>561-732-9722</phone>
      <email>mwells@ccrstudy.com</email>
    </contact>
    <investigator>
      <last_name>Madeline DuPree, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Lojacono</last_name>
      <phone>904-383-1177</phone>
      <email>mlojacono01@bgclinic.com</email>
    </contact>
    <investigator>
      <last_name>Bharat Misra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital Gastroenterology</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Morillo</last_name>
      <phone>305-243-6405</phone>
      <email>dmorillo@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>David Kerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Gastroenterology Ctr</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Davis</last_name>
      <phone>386-767-8800</phone>
      <phone_ext>6676</phone_ext>
      <email>ndavis@amrcus.com</email>
    </contact>
    <investigator>
      <last_name>Ammar Hemaiden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa McCullars</last_name>
      <phone>318-807-0819</phone>
      <email>mmccullars@gastromds.com</email>
    </contact>
    <investigator>
      <last_name>Bal Raj Bhandari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capital Digestive Care, LLC - Metropolitan Gastroenterology Group (MGG)</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Tracey</last_name>
      <phone>301-652-5520</phone>
      <email>kathy.tracey@capitaldigestivecare.com</email>
    </contact>
    <investigator>
      <last_name>Robert Hardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haley Etskovitz</last_name>
      <phone>617-667-3197</phone>
      <email>hetskovi@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Moss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Network</name>
      <address>
        <city>Marlborough</city>
        <state>Massachusetts</state>
        <zip>01752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyle Magner</last_name>
      <phone>508-320-9248</phone>
      <email>kmagner@comcast.net</email>
    </contact>
    <investigator>
      <last_name>John Curran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Dahle</last_name>
      <phone>507-266-4728</phone>
      <email>denise.dahle2@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Loftus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Long Island Clinical Research Associates</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Dufficy</last_name>
      <phone>516-466-1051</phone>
      <email>heather.dufficy@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Robert Tepper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Concorde Medical Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Cadet</last_name>
      <phone>212-899-5544</phone>
      <phone_ext>154</phone_ext>
      <email>dcadet@concordemed.com</email>
    </contact>
    <investigator>
      <last_name>Caterina Oneto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikki Sandridge</last_name>
      <phone>919-966-6806</phone>
      <email>mikki.sandridge@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Hans Herfarth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Cantrell</last_name>
      <phone>919-636-0484</phone>
      <email>celeste.cantrell@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Hans Herfarth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha Peery</last_name>
      <phone>919-781-2514</phone>
      <email>mpeery@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>Charles Barish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Potts</last_name>
      <phone>704-647-9913</phone>
      <email>kpotts@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>Kiran Jagarlamudi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Barker</last_name>
      <phone>336-768-8062</phone>
      <email>gina.barker@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>Robert Holmes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Landry</last_name>
      <phone>615-322-4573</phone>
      <email>erin.vozar@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Dawn Beaulieu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>September 2, 2016</last_update_submitted>
  <last_update_submitted_qc>September 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

